How to buy Minerva Neurosciences stock (NERV)

Minerva Neurosciences is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.12 – a decrease of 0.93% over the previous week. Minerva Neurosciences employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Minerva Neurosciences stock

Buy Minerva Neurosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Minerva Neurosciences stock price (NASDAQ: NERV)

Use our graph to track the performance of NERV stocks over time.

Minerva Neurosciences shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$2.12
52-week range	$2.06 - $13.49
50-day moving average more info button	$2.31
200-day moving average more info button	$2.67
Wall St. target price	$5.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.45

Is it a good time to buy Minerva Neurosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Minerva Neurosciences price performance over time

Historical closes compared with the close of $2.12 from 2024-12-24

1 week (2024-12-19)	-0.93%
1 month (2024-11-26)	-2.30%
3 months (2024-09-26)	-22.06%
6 months (2024-06-26)	-32.70%

1 year (2023-12-26)	-67.53%
2 years (2022-12-23)	-14.52%
3 years (2021-12-23)	7.7184
5 years (2019-12-26)	55.12

Minerva Neurosciences financials

Gross profit TTM	$-16,838,947
Return on assets TTM	-28.91%
Return on equity TTM	-675.09%
Profit margin	0%
Book value	$-3.10
Market Capitalization more info button	$14.8 million

TTM: trailing 12 months

Minerva Neurosciences share dividends

We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.

Have Minerva Neurosciences's shares ever split?

Minerva Neurosciences's shares were split on a 1:8 basis on 20 June 2022 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Minerva Neurosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Minerva Neurosciences shares which in turn could have impacted Minerva Neurosciences's share price.

Minerva Neurosciences share price volatility

Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $2.06 up to $13.49. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is 0.17. This would suggest that Minerva Neurosciences's shares are less volatile than average (for this exchange).

Minerva Neurosciences overview

Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. .

Frequently asked questions

What percentage of Minerva Neurosciences is owned by insiders or institutions?
Currently 22.257% of Minerva Neurosciences shares are held by insiders and 30.473% by institutions. How many people work for Minerva Neurosciences?
Latest data suggests 9 work at Minerva Neurosciences. When does the fiscal year end for Minerva Neurosciences?
Minerva Neurosciences's fiscal year ends in December. Where is Minerva Neurosciences based?
Minerva Neurosciences's address is: 1500 District Avenue, Burlington, MA, United States, 01803 What is Minerva Neurosciences's ISIN number?
Minerva Neurosciences's international securities identification number is: US6033801068 What is Minerva Neurosciences's CUSIP number?
Minerva Neurosciences's Committee on Uniform Securities Identification Procedures number is: 603380106